In a press release dated November 17, Sirona Biochem Corp. announced that results of their latest clinical trials showed the SGLT2 inhibitor dapagliflozin lowered levels of HbA1c blood sugar significantly more than the placebo, and that it was safe and well tolerated with no serious treatment-related adverse events.
The dapagliflozin was effective in patients regardless of disease stage and was associated with continuous weight loss and lowered glycemia without significant hypoglycemia.
Sirona Biochem is a Canadian biotech company focused on diabetes and obesity drug development. The company owns the worldwide exclusive product rights to a library of unique SGLT inhibitors to treat diabetes and obesity through its strategic partnership with TFChem, a drug discovery company based in Rouen, France.
